Evidence map›Paper›PMID 31964754›Full record

ArticleMolecular and cellular biology2020

Therapeutic IDOL Reduction Ameliorates Amyloidosis and Improves Cognitive Function in APP/PS1 Mice.

Jie Gao, Russell Littman, Graciel Diamante, Xu Xiao, In Sook Ahn, Xia Yang, Tracy A Cole, Peter Tontonoz

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular and cellular biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Deletion of neuronal Idol ameliorates Alzheimer's disease-related pathologies via APOE receptors.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  5. Article
  6. Review
  7. Review
  8. Arachidonic Acid Mobilization and Peroxidation Promote Microglial Dysfunction in Aβ Pathology.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2024
    Article
  9. LXR agonism for CNS diseases: promises and challenges.Journal of neuroinflammation · 2024
    Review
  10. Article
  11. Review
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Jie GaoDepartment of Neuroscience, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA Jie.Gao@osumc.edu PTontonoz@mednet.ucla.edu.
Russell LittmanDepartment of Integrative Biology and Physiology, University of California-Los Angeles, Los Angeles, California, USA.
Graciel DiamanteDepartment of Integrative Biology and Physiology, University of California-Los Angeles, Los Angeles, California, USA.
Xu XiaoDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, USA.
In Sook AhnDepartment of Integrative Biology and Physiology, University of California-Los Angeles, Los Angeles, California, USA.
Xia YangDepartment of Integrative Biology and Physiology, University of California-Los Angeles, Los Angeles, California, USA.
Tracy A ColeCentral Nervous System Group, Antisense Drug Discovery, Ionis Pharmaceuticals, Inc., Carlsbad, California, USA.
Peter TontonozDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, USA Jie.Gao@osumc.edu PTontonoz@mednet.ucla.edu.
University of California, Los Angeles · USIonis Pharmaceuticals (United States) · USThe Ohio State University Wexner Medical Center · US

Funding

Training in Molecular ToxicologyT32ES015457 · NIEHS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ALLARD, PATRICK, HANKINSON, OLIVER NMN · 2008 to 2025
$4.0M
Lipid-Responsive E3 ubiquitin ligases in cholesterol metabolism and atheroscierosisR01HL136618 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TONTONOZ, PETER J · 2018 to 2021
$2.4M
DHA Reverses Gene Network Signatures of Fructose-induced Metabolic SyndromeR01DK104363 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI YANG, XIA · 2015 to 2019
$2.4M
Biomedical Big Data Training GrantT32LM012424 · NLM · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI PELLEGRINI, MATTEO · 2016 to 2019
$1.0M
The Idol-ApoE receptor pathway in Alzheimer's diseaseR00AG054736 · NIA · OHIO STATE UNIVERSITY · PI GAO, JIE · 2019 to 2021
$747k
Cell-specific novel genomic biomarkers of TBI pathologyR21NS103088 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GOMEZ-PINILLA, FERNANDO, YANG, XIA · 2017 to 2018
$406k
Biomedical Big Data Training GrantT32CA201160 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI PELLEGRINI, MATTEO · 2015 to 2015
$264k
NCI NIH HHS T32 CA201160NHLBI NIH HHS R01 HL136618NIA NIH HHS R00 AG054736NIDDK NIH HHS R01 DK104363NIEHS NIH HHS T32 ES015457NINDS NIH HHS R21 NS103088NLM NIH HHS T32 LM012424
6 · The paper itself

Abstract

Brain lipoprotein receptors have been shown to regulate the metabolism of ApoE and β-amyloid (Aβ) and are potential therapeutic targets for Alzheimer's disease (AD). Previously, we identified E3 ubiquitin ligase IDOL as a negative regulator of brain lipoprotein receptors. Genetic ablation of

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesAmyloid beta-Protein PrecursorAmyloidosisAnimalsApolipoproteins EBrainCognitionDisease Models, AnimalHippocampusMaleMiceMice, Inbred C57BLMice, TransgenicMicrogliaOligodeoxyribonucleotides, AntisenseAmyloid beta-PeptidesAmyloid beta-Protein PrecursorApolipoproteins EMYLIP protein, humanMylip protein, mouseOligodeoxyribonucleotides, AntisenseReceptors, LDLUbiquitin-Protein LigasesAlzheimersIDOLLXRmacrophagemicroglia

Identifiers

PMID31964754
PMCPMC7108818
OpenAlexW3002043434

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.